GSK plc — Cyborg Score 7/10

Strategic Profile

GSK's R&D pipeline currently includes 64 vaccines and specialty medicines in its four core therapeutic areas of infectious diseases, HIV, oncology and immunology/respiratory. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology. In September 2025, the company announced Emma Walmsley was stepping down as chief executive at the beginning of 2026, with Luke Miels appointed as her replacement.

Cyborg Score Rationale

GSK demonstrates strong fundamentals as a top-10 global pharmaceutical company with a $118B market cap and robust pipeline of 64 vaccines and specialty medicines. Recent acquisitions (RAPT Therapeutics, Syndivia) and strategic pipeline progress show growth momentum, though patent cliff challenges and past regulatory issues warrant attention.

Top Insights

• Strong vaccine portfolio leadership with regulatory approvals continuing (Priorix MMR approved; camlipixant anticipated 2026 launch)
• Active M&A strategy with $2.2B Rapt Therapeutics deal (Jan 2026) and Syndivia prostate cancer drug acquisition
• New CEO leadership transition (Luke Miels effective early 2026) targeting commercial acceleration
• Growing oncology and immunology portfolios complementing core respiratory, antiviral, and HIV franchises

Named Competitors

• Oncology — Leading oncology and diagnostics
• Vaccines — Major vaccine competitor
• Pharmaceuticals — Top pharma with diverse portfolio
• Specialty Pharma — Global specialty pharmaceutical leader
• Respiratory/HIV — Competing in respiratory and specialty pharma

Recent Developments

• (January 2026) Acquired Rapt Therapeutics for $2.2 billion to expand immunology portfolio
• (October 2025) Acquired prostate cancer drug rights from Syndivia for £268 million
• (September 2025) Announced CEO transition with Luke Miels replacing Emma Walmsley effective early 2026

Open the full interactive GSK plc report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.